Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

New Antiviral Approach to HIV Treatment

December 23, 2010 6:12 am | News | Comments

Researchers have discovered how HIV binds to and destroys a specific human antiviral protein called APOBEC3F. The results suggest that a simple chemical change can convert APOBEC3F to a more effective antiviral agent.


Cord Blood Improves Brain Damage

December 23, 2010 6:09 am | News | Comments

In three monthly injections, researchers transplanted neurally-committed, autologous cord blood derived cells tagged with iron oxide nanoparticles into the lateral cerebral ventricle of a 16-month old child with severe global hypoxic ischemic brain injury.


New Drug Class May Treat Anemia

December 23, 2010 6:07 am | News | Comments

By determining how corticosteroids act to promote red blood cell progenitor formation, researchers have identified a class of drugs that may be beneficial in anemias, including those resulting from trauma, sepsis, malaria, kidney dialysis, and chemotherapy.


ProSavin Performs Well in Parkinson's Trial

December 23, 2010 5:53 am | News | Comments

Oxford BioMedica plc announces new data from the on-going Phase 1/2 trial of ProSavin for the treatment of Parkinson’s disease. Three-month data from the third patient cohort show that ProSavin continues to be safe and well-tolerated.


ADVANCE-3 Study Shows Superiority of Apixaban

December 23, 2010 5:46 am | News | Comments

Bristol-Myers Squibb Company and Pfizer Inc. announced study results showing apixaban was statistically superior to 40 mg daily enoxaparin in reducing the incidence of venous thromboembolism in patients undergoing elective total hip replacement surgery.


AZ And Abbott Dissolve Certriad Partnership

December 23, 2010 5:42 am | News | Comments

AstraZeneca PLC and Abbott Laboratories said they are ending a partnership on a cholesterol drug that was rejected by the Food and Drug Administration earlier this year.


Gilead Halts ARTEMIS Trial

December 23, 2010 5:33 am | News | Comments

Gilead Sciences, Inc. announced it is stopping ARTEMIS-IPF, the company's Phase 3 clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis, due to lack of efficacy.


FDA Approves Amturnide

December 23, 2010 5:30 am | News | Comments

Novartis AG said the Food and Drug Administration approved Amturnide, a high blood pressure combination pill that includes Novartis' drug Tekturna.


Abbott Recalling Millions of Testing Strips

December 23, 2010 5:27 am | News | Comments

The Food and Drug Administration said that Abbott Laboratories is recalling up to 359 million testing strips used by diabetics because they can give falsely low blood sugar readings.


Eli And Amylin Ask for Expanded Byetta Approval

December 23, 2010 4:56 am | News | Comments

Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said they are asking the Food and Drug Administration to expand approval for their type 2 diabetes drug Byetta.


Web-Reporting Service

December 22, 2010 7:38 am | Product Releases | Comments

Two Fold Software Limited has created a web reporting module for its Qualoupe LIMS solution that allows organisations such as contract laboratories or manufacturing companies to access and run LIMS reports on demand in a more cost-efficient way.


Diamond-Like Coating

December 22, 2010 7:27 am | Product Releases | Comments

SGE Analytical Science has been awarded a grant to help develop a new diamond-like coating technology. Diamond-like coating technology, or plasma-activated high-frequency vacuum deposition, has low friction and is extremely durable.


Merrion Collaborating With Novo Nordisk

December 22, 2010 7:19 am | News | Comments

Merrion Pharmaceuticals Plc announced the signing of a Collaboration and Option agreement with Novo Nordisk. The agreement will evaluate the ability of Merrion's patented GIPET technology to boost the oral bioavailability of an undisclosed compound.


MorphoSys Receives Centocor Milestone Payment

December 22, 2010 7:14 am | News | Comments

MorphoSys AG has received a clinical milestone payment from Centocor Ortho Biotech Inc. for a clinical trial application for a phase 1 clinical trial of a HuCAL-derived antibody in the therapeutic area of inflammatory and autoimmune diseases.


Cancer Stem Cells Bode Poor Prognosis

December 22, 2010 6:53 am | News | Comments

Researchers have found that leukemia patients whose cancers express higher levels of genes associated with cancer stem cells have a significantly poorer prognosis than patients with lower levels of the genes.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.